These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28753838)

  • 61. Clinical significance of pelvic lymph node status in prostate cancer: review of 1690 cases.
    Maccio L; Barresi V; Domati F; Martorana E; Cesinaro AM; Migaldi M; Iachetta F; Ieni A; Bonetti LR
    Intern Emerg Med; 2016 Apr; 11(3):399-404. PubMed ID: 26875178
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.
    Viers BR; Sukov WR; Gettman MT; Rangel LJ; Bergstralh EJ; Frank I; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ
    Eur Urol; 2014 Dec; 66(6):1116-24. PubMed ID: 25052213
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
    Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
    J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Use of the Prostate Health Index for the Detection of Aggressive Prostate Cancer at Radical Prostatectomy.
    Mearini L; Nunzi E; Ferri C; Bellezza G; Lolli C; Porrozzi C; Porena M
    Urol Int; 2015; 95(4):390-9. PubMed ID: 25792149
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
    Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis.
    Abdollah F; Dalela D; Sood A; Sammon J; Jeong W; Beyer B; Fossati N; Rogers CG; Diaz-Insua M; Peabody J; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
    World J Urol; 2016 Oct; 34(10):1357-66. PubMed ID: 26873596
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?
    Kluth LA; Xylinas E; Rieken M; Chun FK; Fajkovic H; Becker A; Karakiewicz PI; Passoni N; Herman M; Lotan Y; Seitz C; Schramek P; Remzi M; Loidl W; Guillonneau B; Rouprêt M; Briganti A; Scherr DS; Graefen M; Tewari AK; Shariat SF
    Urol Oncol; 2014 Jan; 32(1):47.e1-8. PubMed ID: 24055425
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Trends and Predictors of Adjuvant Therapy for Adverse Features Following Radical Prostatectomy: An Analysis From Cancer of the Prostate Strategic Urologic Research Endeavor.
    Balakrishnan AS; Zhao S; Cowan JE; Broering JM; Cooperberg MR; Carroll PR
    Urology; 2019 Sep; 131():157-165. PubMed ID: 31150694
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Association between Lymph Node Counts and Oncological Outcomes in Lymph Node Positive Prostate Cancer.
    Mandel P; Kriegmair MC; Bogdan K; Boehm K; Budäus L; Graefen M; Huland H; Tilki D
    Eur Urol Focus; 2017 Apr; 3(2-3):248-255. PubMed ID: 28753755
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Adverse Features and Competing Risk Mortality in Patients With High-Risk Prostate Cancer.
    Vagnoni V; Bianchi L; Borghesi M; Pultrone CV; Dababneh H; Chessa F; La Manna G; Rizzi S; Porreca A; Brunocilla E; Martorana G; Schiavina R
    Clin Genitourin Cancer; 2017 Apr; 15(2):e239-e248. PubMed ID: 27641658
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Development and External Validation of Nomograms To Predict Adverse Pathological Characteristics After Robotic Prostatectomy: Results of a Prospective, Multi-institutional, Nationwide series.
    Tosco L; De Coster G; Roumeguère T; Everaerts W; Quackels T; Dekuyper P; Van Cleynenbreugel B; Van Damme N; Van Eycken E; Ameye F; Joniau S;
    Eur Urol Oncol; 2018 Sep; 1(4):338-345. PubMed ID: 31100256
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients.
    Spahn M; Joniau S; Gontero P; Fieuws S; Marchioro G; Tombal B; Kneitz B; Hsu CY; Van Der Eeckt K; Bader P; Frohneberg D; Tizzani A; Van Poppel H
    Eur Urol; 2010 Jul; 58(1):1-7; discussion 10-1. PubMed ID: 20299147
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection.
    Abdollah F; Dalela D; Sood A; Keeley J; Alanee S; Briganti A; Montorsi F; Peabody JO; Menon M
    Eur Urol; 2018 Sep; 74(3):253-256. PubMed ID: 29720348
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Long-Term Mortality in Patients with Positive Lymph Nodes at the Time of Radical Prostatectomy.
    Froehner M; Koch R; Farahzadi S; Heberling U; Borkowetz A; Twelker L; Baretton GB; Wirth MP; Thomas C
    Urol Int; 2019; 103(4):427-432. PubMed ID: 31661703
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The role of volume-weighted mean nuclear volume in predicting disease outcome in patients with prostate cancer treated with radical prostatectomy.
    Fujikawa K; Itoh T; Nishio Y; Miyakawa M; Sasaki M
    APMIS; 1999 Aug; 107(8):773-8. PubMed ID: 10515128
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.
    Lamy PJ; Allory Y; Gauchez AS; Asselain B; Beuzeboc P; de Cremoux P; Fontugne J; Georges A; Hennequin C; Lehmann-Che J; Massard C; Millet I; Murez T; Schlageter MH; Rouvière O; Kassab-Chahmi D; Rozet F; Descotes JL; Rébillard X
    Eur Urol Focus; 2018 Dec; 4(6):790-803. PubMed ID: 28753865
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.
    Lalonde E; Alkallas R; Chua MLK; Fraser M; Haider S; Meng A; Zheng J; Yao CQ; Picard V; Orain M; Hovington H; Murgic J; Berlin A; Lacombe L; Bergeron A; Fradet Y; Têtu B; Lindberg J; Egevad L; Grönberg H; Ross-Adams H; Lamb AD; Halim S; Dunning MJ; Neal DE; Pintilie M; van der Kwast T; Bristow RG; Boutros PC
    Eur Urol; 2017 Jul; 72(1):22-31. PubMed ID: 27815082
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A Nationwide Persistent Underutilization of Adjuvant Radiotherapy in North American Prostate Cancer Patients.
    Rakic N; Sood A; Dalela D; Arora S; Malovana U; Keeley J; Rogers C; Peabody J; Menon M; Abdollah F
    Clin Genitourin Cancer; 2020 Dec; 18(6):489-499.e6. PubMed ID: 32595074
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature.
    Lughezzani G; Briganti A; Karakiewicz PI; Kattan MW; Montorsi F; Shariat SF; Vickers AJ
    Eur Urol; 2010 Nov; 58(5):687-700. PubMed ID: 20727668
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Successful external validation of a model to predict other cause mortality in localized prostate cancer.
    Kent M; Penson DF; Albertsen PC; Goodman M; Hamilton AS; Stanford JL; Stroup AM; Ehdaie B; Scardino PT; Vickers AJ
    BMC Med; 2016 Feb; 14():25. PubMed ID: 26860993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.